Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease

AIMS/INTRODUCTION: Non‐alcoholic fatty liver disease is frequently associated with type 2 diabetes, and constitutes an important risk factor for the development of hepatic fibrosis and hepatocellular carcinoma. Because there remains no effective drug therapy for non‐alcoholic fatty liver disease ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Mitsuko, Hayashi, Akinori, Taguchi, Tomomi, Arai, Riina, Sasaki, Sayaka, Takano, Koji, Inoue, Yusuke, Shichiri, Masayoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626966/
https://www.ncbi.nlm.nih.gov/pubmed/30461221
http://dx.doi.org/10.1111/jdi.12980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626966/
https://www.ncbi.nlm.nih.gov/pubmed/30461221
http://dx.doi.org/10.1111/jdi.12980

Ejemplares similares